ubtd2 Antibody

What is UBTD2 and what are its known biological functions?

UBTD2 is a potential ubiquitin shuttle protein comprised of a Ub-like (UbL) domain and a Ub-binding domain (UBD). It functions in the ubiquitin pathway, potentially mediating protein-protein interactions and ubiquitin-related processes. Research has identified UBTD2 as interacting with deubiquitinating enzyme USP5 and Ub-activating enzyme UbE1, suggesting its role in ubiquitin homeostasis . UBTD2 is also known as Dendritic cell-derived ubiquitin-like protein (DC-UbP) or Ubiquitin-like protein SB72, indicating possible specialized functions in dendritic cells. The protein is approximately 234 amino acids in length with a molecular weight of approximately 26 kDa .

What applications are UBTD2 antibodies commonly used for?

UBTD2 antibodies are primarily utilized in the following applications:

Different antibodies may require optimization of these recommended dilutions for your specific experimental system .

What species reactivity can be expected from UBTD2 antibodies?

Most commercial UBTD2 antibodies demonstrate reactivity with human UBTD2, with varying cross-reactivity to other species:

Species reactivity is often predicted based on sequence homology. For example, percent identity by BLAST analysis shows: Human (100%), Mouse/Rat/Dog/Rabbit/Horse/Pig/Guinea pig/Chicken (92%), and Bovine (85%) .

What are optimal storage conditions for UBTD2 antibodies?

For maximum stability and activity retention:

• Store at -20°C or -80°C according to manufacturer recommendations

• Avoid repeated freeze-thaw cycles

• Most antibodies are supplied in liquid form in stabilizing buffers (typically PBS with 50% glycerol, 0.02% sodium azide, and sometimes BSA)

• For lyophilized antibodies, reconstitute in sterile distilled H₂O with 50% glycerol

• Aliquot antibodies upon receipt to minimize freeze-thaw cycles

How can I validate the specificity of a UBTD2 antibody for my experimental system?

Proper antibody validation is critical for experimental reproducibility. The "antibody characterization crisis" has highlighted that ~50% of commercial antibodies may not meet basic standards for characterization, resulting in billions in financial losses yearly . For UBTD2 antibody validation:

• Positive and negative controls:

  • Use recombinant UBTD2 protein as a positive control

  • Include samples known to express or not express UBTD2

  • Consider UBTD2 knockdown/knockout samples if available

• Multi-technique validation:

  • Compare results across different applications (WB, IHC, IF)

  • Verify that molecular weight in Western blot matches expected size (~26 kDa)

  • Check subcellular localization patterns in IF against literature

• Epitope mapping:

  • Determine the specific region your antibody targets (many UBTD2 antibodies target the C-terminus)

  • Compare results from antibodies targeting different epitopes

  • Consider potential cross-reactivity with similar domains in other proteins

• Enhanced validation methods:

  • Genetic approaches (siRNA, CRISPR/Cas9)

  • Immunoprecipitation followed by mass spectrometry

  • Orthogonal detection methods (RNA expression correlation)

As noted in recent publications, initiatives such as the Recombinant Antibody Network provide resources for validated antibodies with known sequences and characterization data .

What are the known protein-protein interactions of UBTD2 and how can antibodies help study these interactions?

UBTD2 functions as a ubiquitin shuttle protein with several important interactions:

• Key interacting partners:

  • USP5 (deubiquitinating enzyme): UBTD2 interacts with USP5 through its C-terminal UbL domain

  • UbE1 (Ub-activating enzyme): UBTD2 interacts with the UFD domain of UbE1

  • Potentially other ubiquitin pathway components

• Co-immunoprecipitation methodology:

  • Transfect FLAG-tagged DC-UbP/UBTD2 with Myc-USP5 into cells (e.g., HEK 293T)

  • Incubate cell lysates with monoclonal FLAG or Myc antibodies

  • Wash bound beads with lysis buffer and PBS

  • Elute proteins with glycine-HCl buffer (100 mM, pH 3.5)

  • Analyze by SDS-PAGE and immunoblotting

• GST pull-down approach:

  • Express GST-fused domains of interest and His-tagged UBTD2

  • Mix purified GST-fusion proteins with glutathione-agarose beads

  • Add His-tagged UBTD2 and incubate

  • Wash and elute with GSH buffer

  • Analyze by SDS-PAGE and immunoblotting with anti-His antibody

• In vitro activity assays:

  • For deubiquitinating activity: Use Ub-AMC substrate with USP5 in the presence/absence of UBTD2

  • For ubiquitination: Mix UbE1, UbcH5C, Ub and ATP with/without UBTD2

These approaches can help determine how UBTD2 functions in ubiquitin pathway regulation.

How do polyclonal and monoclonal UBTD2 antibodies differ in research applications?

The choice between polyclonal and monoclonal antibodies impacts experimental outcomes:

For critical experiments, consider:

• Using monoclonal antibodies when high specificity is essential

• Using polyclonal antibodies when signal amplification is needed

• Validating results with both types when possible

• Considering recombinant antibodies for highest reproducibility

Recent advances in antibody technology emphasize the value of recombinant antibodies with known sequences to enhance reproducibility .

What epitopes of UBTD2 are commonly targeted and how might this affect experimental outcomes?

Different epitopes can significantly impact antibody performance and experimental results:

• Common epitope targets:

  • C-terminal region: Most commercial antibodies target this region

  • N-terminal region (residues 1-190): Some antibodies target this region

  • Middle domain regions (residues 45-234): Less common target

• Epitope-specific considerations:

  • C-terminal targeting antibodies: May be affected by post-translational modifications or protein-protein interactions at the C-terminus

  • Synthetic peptide vs. recombinant fragment immunogens: Different conformational epitopes may be exposed

• Epitope mapping from literature:

  • The UbL domain (residues 152-225) interacts with UbE1's UFD domain

  • The UBD domain (residues 27-126) is involved in other interactions

  • Key interaction regions may be masked in certain experimental conditions

• Epitope targeting strategies:

  • For detecting total UBTD2: Use antibodies against well-conserved regions

  • For studying specific interactions: Choose antibodies that don't interfere with binding regions

  • For detecting specific forms: Consider antibodies sensitive to post-translational modifications

How can computational approaches improve antibody design for studying UBTD2?

Recent advances in computational antibody design offer promising strategies:

• Model-based approaches:

  • Biophysics-informed models can identify distinct binding modes for antibody-antigen interactions

  • These models can predict and generate specific variants beyond those observed in experiments

  • Selection experiments against combinations of ligands provide training data for computational models

• Active learning for antibody optimization:

  • Starting with small labeled datasets and iteratively expanding labeled data can reduce experimental costs

  • Library-on-library approaches allow identification of specific interacting pairs

  • Recent research developed fourteen novel active learning strategies for antibody-antigen binding prediction

  • The best algorithms reduced required antigen mutant variants by up to 35%

• Application to UBTD2 research:

  • Design antibodies with customized specificity profiles for UBTD2

  • Generate cross-specific antibodies that interact with conserved regions across species

  • Create highly specific antibodies that distinguish UBTD2 from other ubiquitin domain-containing proteins

  • Mitigate experimental artifacts and biases in selection experiments

• Recent case study relevance:

  • Similar approaches led to development of universal COVID-19 antibodies with broad strain recognition

  • The universal antibody 1301B7 binds to multiple positions within its target domain, enabling tolerance of variations

  • This strategy could be applied to develop UBTD2 antibodies resistant to protein conformational changes

How can I optimize Western blot conditions for detecting UBTD2?

For successful UBTD2 detection by Western blot:

• Sample preparation:

  • Ensure complete protein extraction with appropriate lysis buffers

  • Include protease inhibitors to prevent degradation

  • Denature samples thoroughly (95°C for 5 minutes)

• Electrophoresis and transfer:

  • Use 12-15% SDS-PAGE gels for optimal resolution of UBTD2 (~26 kDa)

  • Ensure complete transfer to membrane (verify with Ponceau staining)

• Blocking and antibody incubation:

  • Use recommended dilutions (typically 1:500-1:2000)

  • Optimize blocking reagents (5% BSA or milk)

  • Consider overnight primary antibody incubation at 4°C

• Controls and verification:

  • Include positive control (recombinant UBTD2)

  • Verify expected molecular weight (~26 kDa)

  • Consider loading controls appropriate for your experimental system

• Troubleshooting:

  • For weak signal: Increase antibody concentration, extend incubation time, use signal enhancement systems

  • For high background: Increase washing steps, optimize blocking, decrease antibody concentration

  • For multiple bands: Verify specificity, check for degradation products or post-translational modifications

What are the best practices for immunohistochemistry with UBTD2 antibodies?

For optimal IHC results with UBTD2 antibodies:

• Tissue preparation:

  • Proper fixation is critical (typically 10% neutral buffered formalin)

  • Consider antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0)

  • Use positive control tissues (e.g., human liver or breast cancer tissue)

• Antibody dilution and incubation:

  • Start with recommended dilutions (1:20-1:200)

  • Optimize incubation time and temperature

  • Consider signal amplification systems for low abundance targets

• Detection systems:

  • Choose appropriate detection system (DAB, fluorescence)

  • Include proper counterstaining for tissue architecture

• Controls:

  • Positive control tissues with known UBTD2 expression

  • Negative controls (primary antibody omission)

  • Isotype controls to rule out non-specific binding

• Analysis and interpretation:

  • Document staining patterns (nuclear, cytoplasmic, membranous)

  • Quantify results using appropriate scoring systems

  • Compare patterns with published literature

How can I design experiments to study UBTD2's role in protein ubiquitination pathways?

Based on UBTD2's function as a ubiquitin shuttle protein:

• Interaction studies:

  • Co-immunoprecipitation with known partners (USP5, UbE1)

  • GST pull-down assays to map interaction domains

  • Proximity ligation assays for in situ detection of interactions

• Functional assays:

  • In vitro ubiquitination assays with recombinant proteins

  • Deubiquitination assays using Ub-AMC substrate

  • Effect of UBTD2 on E1-E2 conjugation

• Cellular studies:

  • Overexpression/knockdown effects on global ubiquitination

  • Proteasomal inhibition combined with UBTD2 manipulation

  • Cell stress responses and their effects on UBTD2 function

• Experimental design considerations:

  • Use appropriate negative controls (inactive mutants)

  • Include positive controls (known ubiquitination substrates)

  • Monitor protein levels and localization simultaneously

  • Consider kinetic aspects of ubiquitination processes

How do next-generation antibody technologies apply to UBTD2 research?

Recent advances offering improved specificity and reproducibility:

• Recombinant antibody technology:

  • Sequencing of VH and VL regions from hybridomas enables reproducible antibody production

  • Conversion of monoclonal antibodies to recombinant formats increases consistency

  • Public databases of antibody sequences enhance transparency and reproducibility

• Targeted modifications:

  • N297A modification can prevent antibody-dependent enhancement in therapeutic antibodies

  • Similar modifications might enhance UBTD2 antibody performance in specific applications

• Single-domain antibodies:

  • Nanobodies and other single-domain antibodies offer advantages for targeting specific epitopes

  • Potentially useful for accessing cryptic epitopes in UBTD2

• Future directions:

  • Development of site-specific UBTD2 antibodies targeting post-translational modifications

  • Integration with proximity labeling techniques for identifying interaction networks

  • Combining antibodies with CRISPR/Cas9 screening to identify functional pathways

The lessons from recent antibody development projects, such as NeuroMab and the Protein Capture Reagents Program (PCRP), highlight the importance of rigorous validation and open access to antibody characterization data .

What are the emerging applications of UBTD2 antibodies in disease research?

While specific disease associations for UBTD2 are still being explored:

• Cancer research:

  • UBTD2 antibodies have been tested in human breast cancer tissue

  • The ubiquitin system is frequently dysregulated in cancer

  • UBTD2 antibodies may help characterize altered ubiquitination in tumors

• Neurodegenerative diseases:

  • Ubiquitin pathway disruptions are common in neurodegenerative disorders

  • UBTD2 antibodies could help investigate specific aspects of these pathways

• Immune system regulation:

  • Given UBTD2's original identification in dendritic cells (DC-UbP)

  • Potential role in immune response regulation

• Methodological advances:

  • Integration with multi-omics approaches

  • Single-cell applications for heterogeneity analysis

  • Spatial proteomics to understand UBTD2 localization in disease contexts

The continued development of well-characterized antibodies targeting UBTD2 will facilitate deeper understanding of its roles in normal physiology and disease states.